SCM
ASND icon

Stevens Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Stevens Capital Management’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-3,090
Closed -$298K – 588
2019
Q3 		$298K Buy
+3,090
New +$345K 0.03% 457

Other funds holding ASND

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Stevens Capital Management's ASND Position: Q4 2019 in Review

Stevens Capital Management sold out of Ascendis Pharma A/S (ASND) in Q4 2019, closing a stake of 3,090 shares — an estimated $298K sold.

Stevens Capital Management first reported a position in ASND in Q3 2019 and held it in 1 quarter. The position peaked at $298K in Q3 2019. 143 funds tracked by Wall St. Rank hold ASND as of Q4 2019.

  • Stevens Capital Management reported no remaining Ascendis Pharma A/S position as of Q4 2019 after selling out during the quarter.
  • Stevens Capital Management sold 3,090 Ascendis Pharma A/S shares in Q4 2019, an estimated $298K.
  • Stevens Capital Management first reported a position in Ascendis Pharma A/S in Q3 2019 and held it in 1 quarter.
  • Stevens Capital Management's Ascendis Pharma A/S position peaked at $298K in Q3 2019.
  • 143 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2019.

Based on Stevens Capital Management's 13F filing for Q4 2019, filed 6 Feb 2020.